JCO top-cited
22.01.2018
Our Paper about PIK3CA-Mutations is one of the most-cited papers in JCO.
Our paper about PIK3CA-Mutations from 2014 with 107 citations is one of the most-cited Paper in Journal of Clinical Oncology. We are very proud about this confirmation of the relevance of your research.
"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer."
J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.
News
-
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ... -
05.05.2023 GBG Research at ESMO-BC 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
Mehr ... -
28.02.2023 Annual Scientific Report 2022 published
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
Mehr ... -
24.01.2023 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
Mehr ...